Several members of an FDA advisory committee warned on Monday that new data from studies on long-term use of opioids might ...

PTC Therapeutics announced Monday that its splicing drug for Huntington’s disease met the primary endpoint of a Phase 2 study ...

Bristol Myers Squibb is letting go of 516 workers in New Jersey as part of a wide-reaching cost-cutting plan aimed at making ...

Function Health is buying Ezra in a bid to create a haven for people who want copious amounts of data on their bodies. The ...

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

J&J's gene therapy bota-vec failed Phase 3 trial for X-linked retinitis pigmentosa vision loss. Follows trend of big pharma ...

Deerfield Management is back with its third healthcare venture fund, this time securing more than $600 million to create new ...

FDA delays Stealth BioTherapeutics PDUFA date amid questions about agency disruption, while other companies like Sanofi and J ...

Not many would argue that Biotech is one of the riskiest industries on the globe. With costs hovering in the hundreds of millions of dollars, competitors ...

Topas Therapeutics reveals first data from celiac disease therapy study, showing promise in immune system retraining with ...

Welcome back to Endpoints Weekly, our roundup of the top headlines in biopharma. Earnings season continued this week, with more comments from pharma executives on the potential impact of tariffs ...

Ver­tex is pulling back on its ge­net­ic med­i­cine re­search, end­ing all work re­lat­ed to ade­no-as­so­ci­at­ed virus­es, ...